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ABSTRACT
Background: Psychological distress (PD) has a major impact on quality of life. We studied the inci-
dence of PD before and after radiotherapy for painful bone metastases. Furthermore, we aimed to
identify factors predictive for PD.
Methods: Between 1996 and 1998, the Dutch Bone Metastasis Study included 1157 patients with pain-
ful bone metastases. Patients were randomized between two fractionation schedules. The study
showed a pain response of 74% in both groups. Patients filled out weekly questionnaires for 13 weeks,
then monthly for two years. The questionnaires included a subscale for PD on the Rotterdam
Symptom Checklist. We used generalized estimating equations and multivariable logistic regression
analyses.
Results: At baseline, 290 patients (27%) had a high level of PD. For the entire group, the level of PD
remained constant over time. The majority of patients with a low level of PD at baseline remained at a
low level during follow-up. In patients with a high level of PD at baseline, the mean level of PD
decreased after treatment and stabilized around the cutoff level. Female patients, higher age, worse
performance, lower pain score and worse self-reported QoL were associated with an increased chance
of PD, although the model showed moderate discriminative power.
Conclusions: A substantial proportion of patients had a high level of PD before and after radiotherapy
for painful bone metastases. Most patients who reported high levels of PD when referred for palliative
radiotherapy remained at high levels thereafter. Therefore, screening of PD prior to treatment seems
appropriate, in order to select patients requiring intervention.
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Introduction
Radiotherapy is an effective treatment for patients with pain-
ful bone metastases. The pain response rate is above 60%,
with the golden standard of a single fraction of 8 Gray (Gy)
[1–3]. Although reduction of pain is the main treatment goal,
it is also important to focus on quality of life (QoL) [4].
Painful bone metastases have a negative impact on the QoL
of patients [5,6]. Studies show that radiotherapy stabilizes or
improves QoL [7–15].
Psychological distress (PD) has a major impact on QoL
and is defined as a multi-determined unpleasant emotional
experience that may interfere with the ability to cope effect-
ively with cancer, its physical symptoms and treatment [16].
Symptoms such as nervousness, depressed mood, worrying,
anxiety and irritability contribute to PD [17] and are quite
common in patients with advanced cancer. Nervousness for
example, is experienced by almost 50% of incurable cancer
patients, according to a systematic review in 25,074 patients
[18]. Other symptoms, such as depressed mood, worrying,
anxiety and irritability are reported by 39, 36, 30 and 30% of
patients, respectively.
Up to 50% of patients suffer from PD, however only a small
percentage of them are referred for intervention [19,20].
Routine screening of distress in patients with disseminated
cancer is uncommon [20], despite the fact that several inter-
ventions exist which can decrease PD, such as psychosocial
interventions [21], cognitive therapy [22] or psycho-educa-
tional interventions [23,24]. Some patients disclose the pres-
ence of PD to their health care providers spontaneously and
are therefore easily identified. Other patients do not commu-
nicate or even recognize their PD and its impact. Patients and
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health care providers may also be unaware of the possibility
of interventions to reduce PD [19]. It is therefore important to
identify patients with high levels of PD early, to increase
awareness of both patients and health care professionals on
this topic and if wanted, to offer interventions. Most of the
current literature on PD was acquired in patients with cancer
treated with a curative intent [19,24–28]. To our knowledge,
no studies were performed so far specifically in patients with
bone metastases. No studies reported the extensive course of
PD, both in palliative and curative setting.
In earlier publications we showed that total QoL and its
separate domains, including the psychosocial domain, dimin-
ish towards death [14] and that patients responding to radio-
therapy have a better QoL than non-responding patients [29].
The aim of the present analysis was to focus on the incidence
of PD in patients with painful bone metastases and its course
following palliative radiotherapy. We aimed to identify factors
predictive for PD. For this purpose, the data from the random-
ized Dutch Bone Metastasis Study (DBMS) [1] were used.
Patients and methods
The DBMS was a nationwide, randomized trial in patients
with uncomplicated painful bone metastases. Between 1996
and 1998, 1157 patients were randomized between a single
fraction of 8 Gy or 24Gy in six fractions. The mean age was
65 years (range, 32–89 years). Fifty-four percent of the
patients were male. Most patients had breast cancer (39%),
prostate cancer (23%) or lung cancer (25%). At study inclu-
sion, the mean and median time since diagnosis of the pri-
mary tumor was more than three years and almost two
years, respectively. The median and mean survivals of the
entire group were 30 and 49 weeks, respectively, with a
range of 0.3 to 142 weeks. The study showed the equal
effectiveness of both treatment schedules with regard to
pain response, which was the primary endpoint. All patients
provided informed consent and the Medical Ethics
Committees of participating institutions approved the study.
Further details of the DBMS and the study protocol were
published elsewhere [1,30].
Questionnaires
At randomization and during follow-up, patients filled out
weekly questionnaires for thirteen weeks and then monthly
until two years of follow-up, death or closure of the study in
December 1998. The questionnaires were carried out by mail.
The questionnaires consisted, amongst others, of the
Rotterdam Symptom Checklist (RSCL) [17], a visual analog
general health scale (VAS-gh), a pain scale and pain medica-
tion intake. The RSCL consists of three subscales (psycho-
logical distress, physical symptom distress and activity level
impairment) and a scale for overall valuation of life (on a
seven-point Likert-type scale, with a low score indicating few
or no complaints) (VRS-vl). All other RSCL-items were rated
on a four-point Likert-type scale, ranging from 1 (no com-
plaints at all) to 4 (many complaints). Sum scores were calcu-
lated conforming to the manual of the RSCL, inserting the
personal scale mean of the patient in cases where less than
half of the items of the sum score were missing [17]. At base-
line, the score for the RSCL-subscale for PD was available in
94% of patients. In addition to the RSCL scales, a VAS-gh was
noted on a line from 0 (no complaints) to 100 (worst general
health possible). The advantage of the latter is that each indi-
vidual patient valuates for himself the impact of his com-
bined physical, psychological and functional condition on
their overall perceived general health. Pain was measured
using an 10-point numeric rating scale, ranging from 0 (no
pain) to 10 (the worst pain imaginable). A pain score of at
least 2 was required to enter the study [1].
Psychological distress
The PD subscale of the RSCL consists of seven items, namely
irritability, worrying, depressed mood, nervousness, despair-
ing about the future, tension and anxiety. Since all items are
scored on a four-point Likert-type scale, the total sum score
ranges from 7 (no PD) to 28 (maximum amount of PD) [17].
Ibboston et al. studied the RSCL in 513 cancer patients, in
order to screen for anxiety and depression. The RSCL per-
formed well in patients with progressive disease. A cutoff
point with good sensitivity and specificity for the presence of
PD was determined at 16 [31].
To determine whether patients with an intermediate level
of PD at baseline might have more chance of converting to a
high level of PD during follow-up, the patients below the
cutoff value were divided into two groups: low (7–11) and an
intermediate (12–16) level.
Pain response
Pain response was calculated by taking changes in pain score
and pain medication into account, according to international
criteria [32]. No fixed time interval from the date of random-
ization was applied. A response was calculated if at least two
successive follow-up pain scores were available.
Statistical analyses
Chi-Square tests were used to compare the categorical varia-
bles at baseline. To visualize and compare the course of PD
over time, we used generalized estimating equations (GEE-
measurements), a longitudinal data analysis technique. p val-
ues are based on two-sided tests and considered significant
if p< .05. Figures were created based on the least square
means of the repeated measurements.
To assess which variables were predictive for PD at base-
line, we dichotomized the patients into having or not having
PD (sum score<17 and17). We applied multivariable logis-
tic regression analyses to relate candidate predictors for PD.
First, a full model was used, including all preselected varia-
bles. Subsequently, we eliminated the variables by a back-
ward selection process with a threshold p value of .20, based
on likelihood-ratio test results. The chosen p value of .20
intends to limit the loss of information and to also select
weaker predictors, although at the cost of including ‘noise’
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variables [33]. The preselected baseline variables, based on
the literature and clinical experience, were primary tumor
(breast, prostate, lung or other cancer), age (65 or>65
years), gender (male or female), Karnofsky performance status
(KPS) [34] (60, 70–80 or 90–100), baseline pain score (2–5,
6–7 or 8–10), VRS-vl (1–3 (good), 4 or 5–7 (bad)), VAS-gh
(0–33 (good), 34–66 or 67–100 (bad)), visceral metastases
(yes or no), systemic therapy (yes or no), treatment arm
(6 4Gy or 1 8Gy), pain medication (no opioids or
opioids), localization of pain (extremities, spinal column, pel-
vis or other) and time since diagnosis of primary tumor (con-
tinuous). To prevent that independent variables entered into
the model were correlated with each other, especially those
measuring daily living abilities and general health, we
checked for multicollinearity.
The database was analyzed using IBM SPSS statistics for
Windows version 20.0 (IBM Corp., Armonk, NY, USA) and SAS
software (version 9.2, SAS Institute Inc, Cary, NC, USA).
Results
Relation between patient characteristics and PD at
baseline
In 1084 (94%) patients, the level of PD at baseline could be
calculated. The mean level of PD at baseline was 13.4 for the
entire group, with a median of 12.0. Twenty-seven percent of
patients had a high level of PD at baseline (score 17). Table 1
shows baseline characteristics of the three baseline levels
of PD.
The mean age was 65 years (range 32–89 years). Within
the different groups of primary cancer, 32% of patients with
breast cancer had a high level of distress, compared to 21%
of patients with prostate cancer and 22% of lung cancer
patients. Twenty percent of male patients experienced a high
level of distress, compared to 31% of female patients. There
was a significant gender difference in the 285 patients with
lung cancer and the fourth group consisting of 145 patients
Table 1. Baseline characteristics and level of psychological distress.
PD low PD intermediate PD high Differences
Baseline variables All patients (7 to 11) (12 to 16) (17 to 28) PD unknown between
n 1157 457 337 290 73 p value (p value)
Primary tumor .016
Breast 451 (39%) 161 (36%) 129 (38%) 138 (38%) 23 (32%) Low–intermediate: .414
Prostate 267 (23%) 111 (24%) 87 (26%) 54 (19%) 15 (21%) Low–high:.008
Lung 287 (25%) 119 (26%) 85 (25%) 59 (20%) 24 (33%) Intermediate–high : .025
Other 152 (13%) 66 (14%) 36 (11%) 39 (13%) 11 (15%)
Age .308
65 years 565 (49%) 218 (48%) 178 (53%) 139 (48%) 30 (41%)
>65 years 592 (51%) 239 (52%) 159 (47%) 151 (52%) 43 (59%)
Gender <.001 Low–intermediate: .471
Male 624 (54%) 268 (59%) 189 (56%) 123 (42%) 44 (60%) Low–high: <.001
Female 533 (46%) 189 (41%) 148 (44%) 167 (58%) 29 (40%) Intermediate–high: .001
KPS <.001
90–100 221 (19%) 97 (21%) 80 (24%) 34 (12%) 10 (14%) Low–intermediate: .612
70–80 592 (51%) 244 (53%) 169 (50%) 145 (50%) 34 (47%) Low–high: <.001
20–60 344 (30%) 116 (25%) 88 (26%) 111 (38%) 29 (40%) Intermediate–high: <.001
Pain score .497
2–5 428 (37%) 172 (38%) 123 (37%) 110 (38%) 23 (32%)
6–7 362 (31%) 144 (32%) 118 (35%) 83 (29%) 17 (23%)
8–10 367 (32%) 141 (31%) 96 (29%) 97 (33%) 33 (45%)
VRS-vla <.001 Low–intermediate: <.001
1–3 350 (30%) 189 (41%) 92 (27%) 48 (17%) 21 (29%) Low–high: <.001
4 364 (32%) 152 (33%) 113 (34%) 75 (26%) 24 (33%) Intermediate–high: <.001
5–7 443 (38%) 116 (25%) 132 (39%) 167 (58%) 28 (38%)
VAS-gha <.001
0–33 236 (20%) 127 (28%) 71 (21%) 30 (10%) 8 (11%) Low–intermediate: .043
34–66 530 (46%) 220 (48%) 164 (49%) 108 (37%) 38 (52%) Low–high: .001
67–100 391 (34%) 110 (24%) 102 (30%) 152 (52%) 27 (37%) Intermediate–high: <0.001
Visceral metastases .904
No 838 (72%) 331 (72%) 244 (72%) 214 (74%) 49 (67%)
Yes 319 (28%) 126 (28%) 93 (28%) 76 (26%) 24 (33%)
Systemic therapy .205
No 531 (46%) 215 (46%) 156 (46%) 118 (41%) 42 (57%)
Yes 626 (54%) 242 (54%) 181 (54%) 172 (59%) 31 (43%)
Treatment arm .215
6 4 Gy 578 (50%) 218 (48%) 180 (53%) 138 (48%) 42 (58%)
1 8 Gy 579 (50%) 239 (52%) 157 (47%) 152 (52%) 31 (43%)
Pain medication .112
No opioids 667 (58%) 279 (61%) 200 (59%) 155 (53%) 33 (45%)
Opioids 490 (42%) 178 (39%) 137 (41%) 135 (47%) 40 (55%)
Localization of pain .41
Extremities 173 (15%) 76 (17%) 45 (13%) 44 (15%) 8 (11%)
Spinal column 345 (30%) 119 (26%) 109 (32%) 93 (32%) 24 (33%)
Pelvis 455 (39%) 183 (40%) 134 (40%) 109 (38%) 29 (40%)
Other 184 (16%) 79 (17%) 49 (15%) 44 (15%) 12 (16%)
Pearson Chi-Square.
aVRS-vl and VAS-gh: the lower, the better QoL.
KPS: Karnofsky performance score; VRS-vl: verbal rating score, valuation of life; VAS-gh: visual analog score, general health; Gy: gray.
1722 P. G. WESTHOFF ET AL.
with other primary tumors and their level of PD at baseline.
Thirty-seven percent of these women had a high level of PD,
compared to 21% of male patients (p¼ .016).
There were significant differences between the three
groups in terms of primary tumor, gender, KPS, VRS-vl and
VAS-gh. Patients with a high level of PD at baseline were
more likely to have breast cancer, to be female and to have
a low KPS. They had lower scores for their overall QoL, rated
both visually and verbally. There was no relation between PD
at baseline and mean pain score.
Because we expected patients with a short survival to
have high levels of PD, we analyzed this group separately; of
the 405 patients who died within three months or did not
respond anymore after twelve weeks, 24, 32 and 44% had a
high, intermediate or low level of PD at baseline, respectively.
There was no significant correlation between PD at baseline
and survival.
Prediction of high levels of PD at baseline
In Table 2, the results of multivariate analysis are shown. The
final model to predict a high level of PD at baseline included
age, gender, KPS, pain score, VRS-vl and VAS-gh. Female
patients, higher age, lower performance status, lower pain
score and worse self-reported QoL were associated with an
increased chance of high levels of PD. The area under the
curve of the final model was 0.710, indicating moderate dis-
criminative power. The explained variance was 15.3%.
Course of PD
Figure 1 shows the course of PD over time after treatment.
Figure 1(A) shows the entire group of patients, in which the
mean score of distress remained more or less constant over
time. When excluding the 405 patients who did not return
the questionnaires after three months, due to death (65%) or
other reasons, possibly representing patients in a worse clin-
ical condition, the course of PD remains similar, although
with slightly lower scores (Figure 1(A)). When separating the
patients into three groups with low, intermediate and high
PD at baseline, Figure 1(B) shows that the course of distress
was also rather stable for the low and intermediate group.
For patients with a high level of distress at baseline, the
mean level decreased in the first weeks after treatment and
stabilized around 16 (slightly below the cutoff level). Sixty
percent of patients with an initially high level of PD never
reached a period of several weeks with PD below the thresh-
old value. Of the patients with low or intermediate PD at
baseline, approximately 20% were above the cutoff value of
17 somewhere in the follow-up period. No major differences
in the course of distress between the four different primary
tumors groups were noticed.
Figure 2 shows the proportion of patients with a high,
intermediate or low level of PD. The percentage of patients
with a high level of PD decreases slightly over time, but
remains substantial during the follow-up.
Discussion
We conclude from our analszes that 27% of patients with
advanced cancer referred for palliative radiotherapy for pain-
ful bone metastases, have a high level of psychological dis-
tress when measured on the Rotterdam Symptom Checklist
[17]. Furthermore, we showed that female patients, older
patients, those with a bad performance score, lower pain
score and a low self-reported QoL are at risk for a high level
of PD.
The course of PD following radiotherapy depends mainly
on the level of PD at the start of treatment. In patients with
high levels of distress at baseline the mean level of PD
declined to a level just above the cutoff for having complaints.
Table 2. Univariate (UVA) and final multivariate (MVA) logistic regression anal-
yses on potential baseline predictors for high level of psychological distress
before palliative radiotherapy for painful bone metastases.
Odds ratio (95% CI)
Baseline variables UVAc MVAc
Primary tumor
Breast 1.00 a
Prostate 0.57 (0.40–-0.820)
Lung 0.61 (0.43–0.87)
Other 0.80 (0.53–1.22)
Age
65 years 1.00 1.00
>65 years 1.08 ( 0.83–1.420) 1.28 (0.95–1.73 )
Gender
Male 1.00 1.00
Female 1.84 (1.40–2.42 ) 1.94 (1.44–2.62 )
KPS
90–100 1.00 1.00
70–80 1.83 (1.21–2.76 ) 1.44 (0.92–2.24 )
20–60 2.83 (1.84–4.37 ) 1.67 (1.03–2.70 )
Pain score
2–5 1.00 1.00
6–7 0.85 (0.61–1.18 ) 0.65 (0.46–0.94 )
8–10 1.10 (0.80–1.52 ) 0.60 (0.42 - 0.87)
VRS-vlb
1–3 1.00 1.00
4 1.66 (1.11–2.47) 1.40 (0.91–2.17 )
5–7 3.94 (2.74–5.67) 2.54 (1.63–3.96 )
VAS-ghb
0–33 1.00 1.00
34–66 1.86 (1.20–2.88) 1.43 (0.88–2.31)
67–100 4.73 (3.06–7.32) 2.64 (1.55–4.48)
Visceral metastases
No 1.00 a
Yes 0.93 (0.69–1.26)
Systemic therapy
No 1.00 a
Yes 1.28 (0.97–1.68 )
Treatment arm
6 4 Gy 1.00 a
1 8 Gy 1.11 (0.85–1.45)
Pain medication
No opioids 1.00 a
Opioids 1.32 (1.01–1.74 )
Localization of pain
Extremities 1.00 a
Spinal column 1.12 (0.74– 1.71)
Pelvis 0.95 (0.63–1.42)
Other 0.95 (0.58–1.54)
Time since primary tumor
Continuous 1.00 (1.00–1.00) a
adid not remain in the final model.
bVAS-gh, VRS-vl: the lower the score, the better QoL.
clogistic regression analysis.
KPS: Karnofsky performance score; VRS-vl: verbal rating score, valuation of life;
VAS-gh: visual analog score, general health; Gy: gray; 95% CI: 95% confidence
interval; UVA: univariate analysis; MVA: multivariate analysis
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This might be due to (the expectation of) a pain response
or the attention of caregivers at the radiotherapy depart-
ment, even though, 19% of patients experienced high psy-
chological distress a few weeks after treatment. There is
little change in the level of distress after treatment in
patients with intermediate and low levels of distress at
baseline.
The results may be influenced by the loss of follow-up, as
three months after treatment only 663 patients (57%)
returned questionnaires. This is of course mainly due to the
study population of patients with metastasized cancer and a
limited life expectancy. Theoretically this might influence the
results, since after a few months only the fittest patients
remain, who may be less distressed than those patients
approaching death. Therefore, in Figure 1(A), we excluded
patients with a relatively short survival or those who were
lost to follow-up three months after treatment. When exclud-
ing those patients, the course of PD remains similar, although
this population has a slightly lower level of PD.
The World Health Organization has defined palliative care
as ‘an approach that improves the QoL of patients and their
families facing the problem associated with life-threatening
illness, through the prevention and relief of suffering by
means of early identification and impeccable assessment and
treatment of pain and other problems, physical, psychosocial
and spiritual’ [35]. In patients with advanced cancer, however,
both patients and their health care provider are often
focused on physical symptoms, with less attention for psy-
chosocial problems. Although PD is a common problem
among patients with cancer, many of those patients are not
recognized and referred for interventions [19,20]. Several
interventions for coping with PD exist, such as individual psy-
chological support, support groups or education programs
[20,21,36]. Therefore, screening might be considered. A large
recent review concluded that no specific screening tool for
distress could be recommended [20]. A screening tool which
is often used in Dutch hospitals, the distress thermometer
(Lastmeter) [26], uses dichotomized questions such as ‘do
you feel distressed’, supplemented with the amount of dis-
tress on a scale from 0 to 10. A review including seven
randomized trials showed that screening showed an effect
on psychological well-being in four of the seven trials [37].
Furthermore, screening seems to improve communication
between health care providers and patients and may
enhance psychosocial referrals and facilitate discussions
about QoL [20]. However, it is important to be aware that
not all patients with a high level of PD want to be referred
for an intervention [26]. In a study in 302 cancer patients in
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Figure 1. Mean scores of psychological distress (sum score ranges between 7 (low) and 28 (high)) at baseline (measurement 0) and after radiotherapy for painful
bone metastases. (A) All patients (n¼ 1084) and all patients who still returned their questionnaires after 12 weeks (n¼ 679). (B) Patients with a high (n¼ 290),
intermediate (n¼ 337) and low level (n¼ 457) of psychological distress at baseline. Y-axis: mean scores of psychological distress. X-axis: measurement. The first 12
measurements after baseline were taken weekly and thereafter monthly.
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the Netherlands, mostly treated with curative intent, 51% of
distressed patients did not need an intervention directly after
treatment and 25% were already receiving support. After two
months, regardless of distress level, 10% of all screened
patients reported an unmet need for intervention. The study
showed that the need for an intervention was positively
related to the level of distress [28]. In a study evaluating 361
referrals for psycho-oncological counseling, 20% of newly
referred patients never attended counseling. These patients
were mainly men and patients with lung cancer [36].
Therefore, although identification of distress is important in
order to identify those patients who might benefit from
intervention, referral should be discussed with the individual
patient. A study in 1352 Dutch cancer patients found that
single patients, patients not living with their partner and
patients below 65 years most often wanted an intervention
when highly distressed [27]. In Switzerland, a study investi-
gating the barriers and predictors of patients accepting or
declining psycho-oncological support has recently opened.
The results of this trial should increase the insight into why
not all patients with PD want to be referred for an interven-
tion [38].
To our knowledge, no other papers regarding the inci-
dence and course of PD in patients with bone metastases
treated with palliative radiotherapy have been published,
making it difficult to compare our results with other studies.
A Japanese study in 85 patients with advanced non-small cell
lung cancer, measured PD at diagnosis, after two and six
months, respectively. Forty percent of these patients under-
went radiotherapy. They showed that depression and anxiety
decreased over time, while other dimensions of PD and the
overall level of PD did not. A high level of complaints at
baseline predicted for a high level of complaints during fol-
low-up. Therefore, the authors recommended starting an
intervention shortly after diagnosis [39]. These findings are
largely in line with our results, although we notice a decrease
in overall level of PD in patients with a high level of PD at
baseline.
A study among 149 married cancer patients, mainly with
advanced disease, showed that female patients reported a
higher overall distress than male patients [40]. In the earlier
mentioned Dutch study in 302 cancer patients, female
patients and younger patients were at higher risk of having a
high level of PD [28]. In another paper studying 2776
patients with cancer visiting a tertiary cancer center in
Canada, significant gender differences were found; female
patients reported depressive symptoms more frequently than
male patients and were more likely to receive psychosocial
support [19]. Contrary to our results, they also found younger
patients to be at a higher risk of PD [19], as did a recent
study among breast cancer patients in Morocco [25]. This
might be related to the study populations, namely patients
with all stages of cancer, where the disruption of social life
might be different compared to patients in the palliative
phase.
Surprisingly, the three groups of PD had comparable pain
scores at baseline. One would expect a higher pain score to
be a risk factor for PD, leading to more anxiety, worrying or
depression. Accordingly, in a study among 106 palliative
patients a higher pain score was correlated with increased
distress [41]. In contrast, we found that a lower pain score
predicted for a higher level of PD. We have no clear explan-
ation for this finding.
Our data were collected in the late nineties, which might
be considered as a limitation of our study, since changes in
treatment and subsequent survival may have altered the
course of the disease. Nevertheless, it is based on a unique
and large cohort of patients with bone metastases. Although
the systemic treatment has changed over time, the standard
local treatment for patients with painful bone metastases has
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Figure 2. Percentage of patients with a low, intermediate or high level of PD during follow-up. Y-axis: percentage of patients. X-axis: measurement. The first 12
measurements after baseline were taken weekly and thereafter monthly.
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remained palliative radiotherapy, with a single fraction of
8Gy [2]. Therefore, we believe these results are still applic-
able to current patients with painful bone metastases.
Another possible shortcoming could be that we did not
study patients with painful bone metastases who did not
receive radiotherapy. The course of PD could be a result of
progressive disease.
In conclusion, over 25% of patients referred for palliative
radiotherapy for painful bone metastases have high levels of
PD at baseline, which slightly decreases in the months fol-
lowing treatment. Although palliative radiotherapy is an
effective treatment for pain, these patients still experience
distress. Therefore, we would like to increase awareness in
referring medical specialists and radiation oncologists on the
presence of PD. We advise them to screen patients for PD
and, if present, to make the topic discussable. If wished for,
interventions should be offered, in order to maintain or fur-
ther improve QoL of their patients.
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